Peripherally Restricted NPSR1 Antagonist in Endometriosis

Search and sort the table below for details on projects supported by TIA’s Pipeline Accelerator scheme. TIA voucher outcomes | DOI | Pipeline Accelerator Program | Lead applicant | Affiliation | Project title | Capability provider | |---|---|---|---|---|---| | 10.82292/wqxt-sb11 | 2017-18 | Dr Natalie Borg | Monash University | A broad-spectrum antiviral target and anticancer target | Compounds Australia | | 10.82292/b618-eg41 | 2017-18 | Prof. Charles Mackay | Monash University | Developing an agonistic antibody | Monash Antibody Technologies Facility | | 10.82292/rvve-5697 | 2017-18 | Dr Glen Carter | Peter Doherty Institute/ BioCurate | Development of Novel Gut-Targeted Antibiotics for the Treatment of Multidrug-Resistant Pathogens | Australian Translational Medicinal Chemistry Facility | | 10.82292/fgyv-xh34 | 2017-18 | Dr Christopher J Burns | Metabloq Pty Ltd | High Throughput Screening of Compound Libraries against a Novel Cancer Metabolism Drug Target | ACRF Drug Discovery Centre for Childhood Cancer | | 10.82292/k0xg-5z68 | 2017-18 | Dr Guy Krippner | Baker IDI | Novel Receptor Agonists for difficult to treat chronic illness | Centre for Drug Candidate Optimisation and Australian Translational Medicinal Chemistry Facility | | 10.82292/wzqh-3b09 | 2017-18 | Prof. Spencer Williams | University of Melbourne | Pharmacokinetics and distribution of novel non-steroidal asthma drugs | Centre for Drug Candidate Optimisation | | 10.82292/fkj2-h317 | 2017-18 | Prof. Rajiv Khanna | QIMR Berghofer | The establishment of a repository of in vitro-expanded T cells for the treatment of viral complications in transplant recipients | Q-Gen Cell Therapies | | 10.82292/762z-0m05 | 2017-18 | Dr Susie Nilson | CSIRO | Toxicology and pharmacokinetic profiling of a stem cell mobilisation agent | Centre for Drug Candidate Optimisation and TetraQ | | 10.82292/5wd0-w063 | 2019-20 (Core facilities) | Dr Wim Meutermans | Vast Bioscience Pty Ltd | ADME and PK evaluation of VAST preclinical candidates for postsurgical pain | Centre for Drug Candidate Optimisation | | 10.82292/jsk5-ex93 | 2019-20 (Core facilities) | Dr Nicholas Veldhuis | Monash University | Assessing efficacy of analgesic nanoparticles in chemotherapy-induced neuropathic pain | Centre for Integrated Preclinical Drug Development | | 10.82292/zjbc-5h19 | 2019-20 (Core facilities) | Kevin Isch | NeuClone Pty Ltd | Development and validation of an ECL immunoassay method for quantitation of ustekinumab concentration in human serum | TetraQ | | 10.82292/sf5c-xp13 | 2019-20 (Core facilities) | Prof Tom Gonda | University of South Australia | Development of a small molecule inhibitor of the MYB oncogene as a therapeutic for Acute Myeloid Leukaemia | Australian Translational Medicinal Chemistry Facility | | 10.82292/ek2g-8m20 | 2019-20 (Core facilities) | Mr Gregory Santamaria | Cyclotek (Aus) Pty Ltd | Development of advanced and novel radioligands for Positron Emission Tomography (PET) imaging | Australian Translational Medicinal Chemistry Facility | | 10.82292/wdt2-hx72 | 2019-20 (Core facilities) | Dr Steven Petratos | Monash University | Development of Small Molecules to Promote Remyelination in Multiple Sclerosis | Australian Translational Medicinal Chemistry Facility | | 10.82292/430v-ha46 | 2019-20 (Core facilities) | Dr David Elliott | Murdoch Children’s Research Institute | Identifying compounds that protect against anthracycline induced heart damage | Australian Translational Medicinal Chemistry Facility | | 10.82292/nyyv-rp89 | 2019-20 (Core facilities) | A/Prof Brendon Coventry | Cancuravax Pty Ltd | Melanoma Cancer Vaccine Immunotherapy Production & Scaling for Commercialisation | National Biologics Facility NSW Node | | 10.82292/hkcc-5y29 | 2019-20 (Core facilities) | Prof Katherine Andrews | Griffith Institute for Drug Discovery (GRIDD) | Pre-clinical optimisation studies on a new antimalarial drug lead | Centre for Drug Candidate Optimisation | | 10.82292/ryn7-ha77 | 2019-20 (Core facilities) | Dr Ebony Fietz | Gertrude Biomedical Pty Ltd | Preclinical ADME and PK drug properties of novel inhibitors of SOX18 transcription factor | Centre for Drug Candidate Optimisation | | 10.82292/we6x-j896 | 2019-20 (Core facilities) | Dr Brad Walsh | GlyTherix Ltd | Production and Lead Selection of Humanised Anti-Glypican-1 Antibodies | National Biologics Facility NSW Node | | 10.82292/kdvn-cc47 | 2019-20 (Core facilities) | Prof Bernard Flynn | Monash University | Targeting Sphingosine Kinase 1 for the Treatment of Pulmonary Hypertension | Centre for Drug Candidate Optimisation and TetraQ | | 10.82292/6q6s-2e28 | 2019-20 (Screening) | Dr Nicholas Clemons | Peter MacCallum Cancer Institute | A specific inhibitor of SLC7A11 (XCT) for single agent or combination treatment of cancers with mutant p53 | Victorian Centre for Functional Genomics | | 10.82292/8pan-sd75 | 2019-20 (Screening) | Dr Kathleen Pishas | Peter MacCallum Cancer Institute | Defining the role of clonal interaction in high grade serous ovarian cancer drug resistance | Victorian Centre for Functional Genomics | | 10.82292/q4y3-wk08 | 2019-20 (Screening) | Dr Joseph Brock | ANU | Development of an engineered thermal shift assay for the high-throughput discovery of integral membrane protein lead compounds | ANU Centre for Therapeutic Discovery | | 10.82292/a01f-y528 | 2019-20 (Screening) | Dr Nicholas Eyre | University of Adelaide | Development of inhibitors of dengue virus (DENV) NS1 protein dimerization as novel antiviral therapeutics | Cell Screen SA | | 10.82292/4r6x-5v90 | 2019-20 (Screening) | Dr Dane Cheasley | Peter MacCallum Cancer Institute | High throughput investigation of synergistic drug combinations for patients with low-grade serous ovarian carcinoma | Victorian Centre for Functional Genomics | | 10.82292/bt01-mp70 | 2019-20 (Screening) | Dr Brian Dymock | UniQuest | Identification of Inhibitors of a key oncogenic protein by Fragment Screening | Monash Fragment Platform | | 10.82292/mpdd-h569 | 2019-20 (Screening) | Ms Natasa Broit | QIMR Berghofer | Identification of novel therapies for the treatment of acral lentiginous melanoma | Griffith Discovery Biology | | 10.82292/heze-9j85 | 2019-20 (Screening) | Dr Amee George | ANU | Identifying therapeutics for the treatment of Myelodysplastic Syndrome | ANU Centre for Therapeutic Discovery | | 10.82292/zt8m-n327 | 2019-20 (Screening) | Dr Michael Sharp | St. Vincent’s Institute of Medical Research | Inhibiting the Fanconi Anaemia pathway to target BRCA1/2 negative breast and ovarian cancers | Victorian Centre for Functional Genomics | | 10.82292/ysy8-g459 | 2019-20 (Screening) | Prof Si Ming Man | ANU | Novel antitoxin compound discovery for the treatment of antibiotic resistant bacteria | ANU Centre for Therapeutic Discovery | | 10.82292/3xq0-6w79 | 2019-20 (Screening) | Prof Brian Gabrielli | TRI | Screen for new agents to selectively kill a novel defect in melanomas | ACRF Drug Discovery Centre | | 10.82292/k56b-4a93 | 2019-20 (Screening) | Dr Benjamin Blasco | GARDP | The discovery and development of novel antibiotics against MDR and XDR Gram-negative pathogens | CO-ADD | | 10.82292/bvy8-na90 | 2020 COVID-19 | Dr Keith Dredge | Zucero Therapeutics Ltd | Analytical and bioanalytical development of pixatimod (ZU545/PG545)- a clinical candidate for cancer with anti-viral and anti-inflammatory properties - to support clinical testing for Covid-19” | TetraQ | | 10.82292/yks2-cn38 | 2020 COVID-19 | Dr Cameron Stewart | Australian Centre for Disease Prevention (ACDP), CSIRO | Defining the role of host microRNAs in COVID-19” | Victorian Centre for Functional Genomics | | 10.82292/5dsd-4g64 | 2020 COVID-19 | Prof Terrance Johns | Telethon Kids Institute | Discovery of antibodies to the furin cleavage site of SARS-CoV-2 Spike Glycoprotein | National Biologics Facility Queensland Node | | 10.82292/c6za-fg83 | 2020 COVID-19 | Dr Arun Konagurthu | Monash University | Modelling, synthesis and testing of potential agents against COVID-19 main protease | Australian Translational Medicinal Chemistry Facility | | 10.82292/fbdd-8x59 | 2020 COVID-19 | Dr Charles Bailey | Centenary Institute | Monitoring the therapeutic efficacy of BD-218, a human neutralising monoclonal antibody against SARS-CoV-2, in COVID-19 patients using Nanostring gene expression analysis | Cell & Molecular Therapies, Royal Prince Alfred Hospital | | 10.82292/arkh-1133 | 2020 COVID-19 | Prof Bevyn Jarrott | Vailima Peninsula Pty Ltd | Pre-clinical development of a novel, patented small molecule to treat COVID-19 respiratory injury | Centre for Drug Candidate Optimisation | | 10.82292/f7fc-cm44 | 2020 COVID-19 | A/Prof Severine Navarro | QIMR Berghofer Medical Research Institute | Prevention of COVID-19-induced hyperinflammatory syndrome with the immunomodulatory protein AIP-2” | National Biologics Facility Queensland Node | | 10.82292/0rjv-pk12 | 2020 COVID-19 | Dr Richard Angell | University College London | Using fragment-based drug discovery to identify small molecule inhibitors of SARS-CoV-2 (COVID-19) RNA-dependent RNA polymerase (RdRp) and future starting points for other Coronaviruses | Monash Fragment Platform | | 10.82292/gz6e-xa19 | 2020-21 (Round 1) | Prof. Peter Timms | University of Sunshine Coast | Development of a chlamydial vaccine for koalas: Production of chlamydial proteins at high quality suitable for vaccine trials | National Biologics Facility Victoria Node | | 10.82292/rcap-jg76 | 2020-21 (Round 1) | Prof. Alastair Stewart | Tianli Biotech Pty Ltd | Development of casein kinase 1 delta inhibitors for inflammation, fibrosis and fibrotic cancers | Centre for Drug Candidate Optimisation | | 10.82292/racg-1y66 | 2020-21 (Round 1) | Dr. Fernando S. F. Guimaraes | University of Queensland | Development of new anti-breast cancer antibodies for natural killer (NK) cell-based immunotherapy | National Biologics Facility Queensland Node | | 10.82292/jp96-pz29 | 2020-21 (Round 1) | Prof. Ian Smyth | Monash University | Inhibiting cystogenesis in Polycystic Kidney Disease with AURKA PROTACs | Australian Translational Medicinal Chemistry Facility | | 10.82292/33k4-8a30 | 2020-21 (Round 1) | Prof. Alex Loukas | James Cook University | Innovative IBD biologics inspired by host-parasite coevolution | National Biologics Facility Queensland Node | | 10.82292/ad6r-m163 | 2020-21 (Round 1) | Dr Stuart Fraser | University of Sydney | Nanions: a rapid, non-toxic nanoparticle vaccine platform | TetraQ | | 10.82292/cppe-ws05 | 2020-21 (Round 1) | Dr. Christopher Burns | MycRx Pty Ltd | Novel, small-molecule therapeutics for the treatment of cancers addicted to the oncoprotein Myc | Centre for Drug Candidate Optimisation | | 10.82292/xdjj-az48 | 2020-21 (Round 1) | Dr. Brad Walsh | Glytherix Ltd | Optimisation and Characterisation of Miltuximab-DFO Bioconjugation | National Biologics Facility Victoria Node | | 10.82292/3n7f-na05 | 2020-21 (Round 1) | Prof. Andrew Prowse | University of Queensland | Pilot scale GMP production of cardiomyocytes derived from human pluripotent stem cells | Q-Gen Cell Therapeutics | | 10.82292/mvfh-3q50 | 2020-21 (Round 1) | Prof. Mark von Itzstein | Griffith University | Preclinical development of a drug lead candidate against human parainfluenza virus – Exploratory pharmacokinetic, toxicity, and metabolic studies | TetraQ and Centre for Drug Candidate Optimisation | | 10.82292/jgzw-wk34 | 2020-21 (Round 1) | Prof. Suddha Rao | QIMR Berghofer Medical Research Institute | Safety and pharmacokinetics study of a novel anti-PD-L1 therapeutic to improve immunotherapy in triple-negative breast cancer | TetraQ | | 10.82292/h5z5-zs57 | 2020-21 (Round 1) | Prof. John Hooper | Mater Research Institute | Screening for a manufacturable antibody variant for PET-CT imaging of ovarian cancer | National Biologics Facility Queensland Node | | 10.82292/83rz-6a28 | 2020-21 (Round 1) | Dr Michael Thurn | Botanix Pharmaceuticals | Studies of Bacterial Resistance Induced by Cannabidiol (CBD) | CO-ADD | | 10.82292/4m39-h714 | 2020-21 (Round 1) | Dr Mark Del Borgo | Monash University | Synthesis of novel peptide mimics for use as anti-fibrotic agents | Australian Translational Medicinal Chemistry Facility | | 10.82292/hn16-tr22 | 2020-21 (Round 1) Screening | A/Prof Marco Casarotto | Australian National University | Developing therapeutics that treat/prevent ischemia reperfusion injury (IRI) | ANU Centre for Therapeutic Discovery | | 10.82292/x2jd-zp37 | 2020-21 (Round 1) Screening | Prof. Ian Street | Children's Cancer Institute | Development of a high-throughput screening assay for a novel activated kinase ALPK1 | ACRF Drug Discovery Centre | | 10.82292/vqce-2a41 | 2020-21 (Round 1) Screening | Prof. Murray Whitelaw | University of Adelaide | Discovery and development of new antimicrobials to combat antibiotic resistance | GRIDD Mass Spectrometry Screening Platform | | 10.82292/8vrj-gg45 | 2020-21 (Round 1) Screening | Assoc. Prof. Leonie Quinn | Australian National University | High-Throughput 3D Cell and Organism Screening for new brain cancer (glioma) treatments | ANU Centre for Therapeutic Discovery | | 10.82292/1z7m-4v02 | 2020-21 (Round 1) Screening | Dr Shom Goel | Peter MacCallum Cancer Centre | Improving outcomes for breast cancer patients receiving CDK4/6 inhibitors | Victorian Centre for Functional Genomics | | 10.82292/bkxp-dq96 | 2020-21 (Round 1) Screening | Prof. Sally-Ann Poulsen | Griffith University | Restoring the efficacy of chemotherapy in drug resistant cancers | Discovery Biology | | 10.82292/e34x-dg73 | 2020-21 (Round 1) Screening | Dr. Eleanor Saunders | University of Melbourne | Targeting human leishmaniasis | Victorian Centre for Functional Genomics | | 10.82292/mhyv-kp21 | 2020-21 (Round 2) | Dr Mitali Sarkar-Tyson | University of Western Australia | Advanced development of therapeutics against bacterial pathogens of biowarfare concern | Australian Translational Medicinal Chemistry Facility | | 10.82292/v22q-gc78 | 2020-21 (Round 2) | Dr Chris Langmead | Monash University | Development of biased agonists for schizophrenia | Centre for Drug Candidate Optimisation and Australian Translational Medicinal Chemistry Facility | | 10.82292/4g19-6b52 | 2020-21 (Round 2) | A/Prof Ashley Buckle | Monash University | Development of novel anti-inflammatory biologics | National Biologics Facility Queensland Node | | 10.82292/ccsp-n477 | 2020-21 (Round 2) | Dr Julian Barden | Biosceptre Aust Pty Ltd | Development of novel cellular cancer therapeutics | National Biologics Facility NSW Node | | 10.82292/px16-ea35 | 2020-21 (Round 2) | Dr Pegah Varamini | University of Sydney | Development of novel therapeutics for targeted therapy of triple negative breast cancer | Centre for Integrated Preclinical Drug Development | | 10.82292/qwch-v272 | 2020-21 (Round 2) | Dr Paul Stupple | CTx/Monash University | In vivo and in vitro pharmacokinetic studies of novel therapeutics against blood cancers | Centre for Drug Candidate Optimisation | | 10.82292/wqeb-0y94 | 2020-21 (Round 2) | A/Prof Daniel Thomas | University of Adelaide | Iterative design of selective Type II JAK2 Inhibitor for superior management of myelofibrosis | Australian Translational Medicinal Chemistry Facility | | 10.82292/rrrd-7171 | 2020-21 (Round 2) | Dr Chengxue Helena Qin | Monash University | Next generation formyl peptide receptor 2 agonists to treat pulmonary hypertension | Australian Translational Medicinal Chemistry Facility | | 10.82292/0tv1-yt05 | 2020-21 (Round 2) | Dr Nadia Warner | Peter Doherty Institute for Infection and Immunity | Synthesis and development of targeted degraders of the hepatitis B virus (HBV) core proteins for HBV therapy | Australian Translational Medicinal Chemistry Facility | | 10.82292/cgp4-vr86 | 2020-21 (Round 2) | Dr Mark Devlin | Aculeus Therapeutics Pty Ltd | Systemically delivered small molecule STING agonists as next generation cancer immunotherapies | Centre for Drug Candidate Optimisation | | 10.82292/e4d4-6y80 | 2020-21 (Round 2) | Prof Elizabeth Coulson | University of Queensland | Therapeutic antibody discovery to block neurotrophin receptor cleavage | National Biologics Facility Queensland Node | | 10.82292/zmv7-0d15 | 2020-21 (Round 2) Screening | Prof Frederic Hollande | University of Melbourne | Developing a combined small molecule and immune cell killing assay to identify new therapeutics in pancreatic cancer” | Victorian Centre for Functional Genomics | | 10.82292/eh05-1n71 | 2020-21 (Round 2) Screening | A/Prof Ethan D. Goddard-Borger | WEHI | Developing fucosyltransferase inhibitors as treatments for rare leukaemia | Monash Fragment Platform | | 10.82292/dh48-dy71 | 2020-21 (Round 2) Screening | A/Prof Ian Street | Children's Cancer Institute | Development of an assay system to identify CNS-penetrant derivatives of pre-existing drugs for brain cancer | ACRF Drug Discovery Centre | | 10.82292/3th3-pc66 | 2020-21 (Round 2) Screening | Prof Mark Dawson | Peter MacCallum Cancer Centre | Identification of novel immune-checkpoint therapies to inhibit interaction between PD-L1 and CMTM6, a new regulator of anti-tumour immunity | Discovery Biology | | 10.82292/m6n8-j063 | 2020-21 (Round 2) Screening | Dr Jess Tiffen | Centenary Institute | Identifying Epigenetic Drivers of Drug Resistant Melanoma | Discovery Biology | | 10.82292/ej2n-6y69 | 2020-21 (Round 2) Screening | Prof Klaus-Martin Schulte | Australian National University | Identifying therapeutics for the treatment of advanced BRCA2 breast cancer” | ANU Centre for Therapeutic Discovery | | 10.82292/eqm2-hx66 | 2021-22 (Round 1) | Dr Gonzalo Perez-Siles | ANZAC Research Institute | Development of a high throughput screening platform of patient-derived iPSC motor neuron for enhancers of energy metabolism as a therapeutic intervention in axonal degeneration | Victor Chang Cardiac Research Institute | | 10.82292/78nj-5y69 | 2021-22 (Round 1) | Dr Robert Feldman | COVID-19 Vaccine Corporation | Development of an mRNA cytotoxic T-cell COVID-19 vaccine | BASE Facility | | 10.82292/qene-q522 | 2021-22 (Round 1) | A/Prof Jonathan S. Oakhill | St Vincent's Institute of Medical Research | Development of CaMKK2 inhibitors as new cancer therapies | Centre for Drug Candidate Optimisation | | 10.82292/kw2f-8110 | 2021-22 (Round 1) | Dr Chisha Teza Sikazwe | PathWest Laboratory Medicine WA | Development of recombinant MVEV and JEV NS1 antigen for the detection of JEV and MVEV antibody in serum | Protein Expression Facility | | 10.82292/039z-zw14 | 2021-22 (Round 1) | Dr Willem Joost Lesterhuis | Telethon Kids Institute | Development of small molecule drugs in immuno-oncology | Centre for Drug Candidate Optimisation | | 10.82292/bbkh-7961 | 2021-22 (Round 1) | Dr Ben Rollo | Monash University | Human high-throughput in-vitro phenotypic screening for new epilepsy drugs | Compounds Australia | | 10.82292/f7y7-dg28 | 2021-22 (Round 1) | Prof Sudha Rao | QIMR Berghofer | Identification of a small molecule inhibitor for therapeutic targeting of a novel nuclear methyltransferase in immunotherapy-resistant metastatic cancers | GRIDD Mass Spectrometry Screening | | 10.82292/vaha-4449 | 2021-22 (Round 1) | Prof Ian Smyth | Monash University | Inhibiting cyst formation in polycystic kidney disease with targeted protein degraders (TPDs) | Australian Translational Medicinal Chemistry Facility | | 10.82292/1kte-3j11 | 2021-22 (Round 1) | Dr Samantha South | Argenica Therapeutics Ltd | Neuroprotective efficacy of poly-argine-18 (R18) in a relapsing-remitting experimental autoimmune encephalomyelitis (RR-EAE) mouse model of multiple sclerosis (MS) | Centre for Integrated Preclinical Drug Development | | 10.82292/tpq5-vs48 | 2021-22 (Round 1) | Dr Mitchell Lawrence | Monash University | New generation combination therapies for advanced prostate cancer | Victorian Centre for Functional Genomics | | 10.82292/kst8-nc49 | 2021-22 (Round 1) | Prof John EJ Rasko | Centenary Institute | Novel gene therapy platforms for hemophilia B | Vector and Genome Engineering Facility | | 10.82292/6q9k-tv80 | 2021-22 (Round 1) | Prof John Hooper | Mater Research Institute | Process development to optimise and characterise the conjugation process of DFO and monoclonal antibody 10D7 | National Biologics Facility Victoria Node | | 10.82292/942k-5h71 | 2021-22 (Round 1) | A/Prof Jenny Gunnersen | University of Melbourne | Screening for therapeutic antibodies to treat chronic pain | National Biologics Facility Queensland Node | | 10.82292/whba-j504 | 2021-22 (Round 1) | Dr Nicholas Hunt | University of Sydney | Synthesis and characterisation of Ag2S quantum dots and conjugation to insulin at CSIRO | National Biologics Facility Victoria Node | | 10.82292/fb56-v382 | 2021-22 (Round 1) | A/Prof Nick Clemons | Peter MacCallum Cancer Centre | Synthesis of novel small molecule inhibitors of SLC7A11/XCT for mutant-p53 cancers | Australian Translational Medicinal Chemistry Facility | | 10.82292/amqc-ww10 | 2021-22 (Round 1) | Prof Rajiv Khanna | QIMR Berghofer | The establishment of a repository of in vitro-expanded cytomegalovirus-specific T cells for the treatment of glioblastoma multiforme | Q-Gen Cell Therapeutics | | 10.82292/rpkh-4062 | 2021-22 (Round 1) | Dr Marie Besnier | University of Sydney | Treating the mitochondria to improve endothelial function of patients with coronary artery disease | Victor Chang Cardiac Research Institute | | 10.82292/jwff-wh96 | 2021-22 (Round 2) | Prof Timothy Stinear | University of Melbourne | A high-throughput screening campaign to find inhibitors of intracellular multi-drug resistant Staphylococcus aureus | Victorian Centre for Functional Genomics | | 10.82292/9x7g-6526 | 2021-22 (Round 2) | Dr Sohinee Sarkar | Murdoch Children's Research Institute | A new treatment for the cystic fibrosis superbug, Mycobacteroides abscessus | Compounds Australia | | 10.82292/8vfk-gq55 | 2021-22 (Round 2) | Dr Sarah Jones | Monash University | A novel Glucocorticoid (GC) mimic for the treatment of inflammatory and autoimmune diseases | National Biologics Facility Victoria Node | | 10.82292/rv6t-qq90 | 2021-22 (Round 2) | Dr Katherine Locock | CSIRO | Accelerated antibiotic discovery through high-throughput | Compounds Australia and Community for Open Antimicrobial Drug Discovery | | 10.82292/04xr-kd12 | 2021-22 (Round 2) | Prof Kristen Radford | Mater Research Institute | Development of human CLEC9A antibodies as cancer vaccines | National Biologics Facility Queensland Node | | 10.82292/d71k-1f86 | 2021-22 (Round 2) | Prof Christopher Langmead | Monash Institute of Pharmaceutical Sciences | Development of novel agonists for schizophrenia | Australian Translational Medicinal Chemistry Facility | | 10.82292/kxqp-pe64 | 2021-22 (Round 2) | A/Prof Kara Britt | Peter MacCallum Cancer Centre | Identify drugs that selectively inhibit oestrogen receptor positive luminal progenitor activity | Victorian Centre for Functional Genomics | | 10.82292/jvaa-wt45 | 2021-22 (Round 2) | Dr Thomas Theodor Tapmeier | Monash University | NPSR1 Antagonist in Endometriosis | Australian Translational Medicinal Chemistry Facility | | 10.82292/kqk7-9y94 | 2021-22 (Round 2) | Prof Ian Smyth | Monash University | Pharmacokinetic Assessments and optimisation of a new therapy for PKD | Australian Translational Medicinal Chemistry Facility and Centre for Drug Candidate Optimisation | | 10.82292/vrwd-vv53 | 2021-22 (Round 2) | A/Prof Rebecca Lim | Hudson Institute of Medical Research | Phase II Amnion Cell Therapy in Ischemic Stroke | Q-Gen Cell Therapeutics | | 10.82292/qtp6-q395 | 2021-22 (Round 2) | Dr William Thomas Jorgensen | Psylo Pty Ltd | Pre-clinical development of novel serotonergic agents for therapeutic applications in mental illness | Centre for Drug Candidate Optimisation | | 10.82292/t22t-3k37 | 2021-22 (Round 2) | A/Prof Rebecca Lim | Prescient Therapeutics | Preclinical toxicity studies for OmniCAR-enabled targeting ligands | National Biologics Facility Queensland Node | | 10.82292/pdk6-cq90 | 2021-22 (Round 2) | Dr Nicole Van Bergen | Murdoch Children’s Research Institute | Utilising high-throughput drug screening for mitochondrial metabolite repair disorders | Compounds Australia | | 10.82292/0xas-sy75 | 2022-23 (Round 1) | A/Prof Daniel Thomas | University of Adelaide | Anti-mutant CALR Antibody Preparation for Clinical Manufacture for Patients with Myelofibrosis | National Biologics Facility Queensland Node | | 10.82292/2ke6-n640 | 2022-23 (Round 1) | Prof Andrew Elefanty | Murdoch Children's Research Institute | Building a better leukaemia – Modeling paediatric acute myeloid leukaemia in pluripotent stem cells | Stafford Fox Disease Modelling Facility | | 10.82292/nx3m-yj92 | 2022-23 (Round 1) | Prof Philip Board | Omega-One Therapeutics Pty. Ltd. | Developing Glutathione transferase Omega 1 inhibitors as anti-inflammatory therapeutics | Australian Translational Medicinal Chemistry Facility | | 10.82292/zmv0-kz47 | 2022-23 (Round 1) | Prof Enzo Porrello | Murdoch Children's Research Institute | Developing next generation cardio-regenerative therapeutics to treat systolic heart failure | Australian Translational Medicinal Chemistry Facility | | 10.82292/2vxe-g490 | 2022-23 (Round 1) | A/Prof Silvia Velasco | Murdoch Children's Research Institute | Development of a platform for the automated generation and high-throughput drug screening of brain organoids | Stafford Fox Disease Modelling Facility | | 10.82292/nb9c-p530 | 2022-23 (Round 1) | Prof Mark von Itzstein | Institute for Glycomics, Griffith University | Development of drug candidates against drug resistant bacteria | Centre for Drug Candidate Optimisation | | 10.82292/z4y9-1t06 | 2022-23 (Round 1) | A/Prof Elaine Sanij | St Vincent's Institute of Medical Research | Development of new cancer therapeutics targeting the nucleoli | Victorian Centre for Functional Genomics | | 10.82292/6m3f-t539 | 2022-23 (Round 1) | Prof Alastair Stewart | University of Melbourne | Discovery of selective inhibitors for fibrosis | Monash Fragment Platform | | 10.82292/381q-mx16 | 2022-23 (Round 1) | Mr Paul Fahey | Vaxxas Pty. Ltd. | Enhanced skin delivery of vaccines by manipulating surface interactions on High Density Micro Array Patches (HD-MAP’s). | National Biologics Facility Victoria Node | | 10.82292/ym35-5439 | 2022-23 (Round 1) | Dr Steve Dingwall | Australian Institute for Bioengineering and Nanotechnology | Generation of Induced Pluripotent Stem Cell Master and Working Cell Banks for a Phase 1 Clinical Trial for the Treatment of Heart Failure | Q-Gen Cell Therapeutics | | 10.82292/407e-8568 | 2022-23 (Round 1) | Dr Jacek Kwiatkowski | Queensland Emory Drug Discovery Initiative | Identification of Inhibitors of a Key Necroptotic Protein Through Fragment Screening | Monash Fragment Platform | | 10.82292/fc3p-vs14 | 2022-23 (Round 1) | Ms Filippa Shub | Inosi Therapeutics | IRAP inhibitor lead optimisation | Centre for Drug Candidate Optimisation | | 10.82292/kk94-5x14 | 2022-23 (Round 1) | Prof Robyn Jamieson | Children's Medical Research Institute | Long-term AAV-mediated genetic rescue of photoreceptors in retinitis pigmentosa | Sydney Cell and Gene Therapies | | 10.82292/a4tf-4810 | 2022-23 (Round 1) | A/Prof James Chong | Westmead Institute for Medical Research | Process development for the preparation and delivery of induced pluripotent stem cell derived cardiomyocytes for end stage heart failure. | Sydney Cell and Gene Therapy | | 10.82292/h0ah-jd02 | 2022-23 (Round 1) | Dr Graham Heery | Starpharma Pty Ltd | Production of a HER2 binding nanobody for the assembly of targeted novel dendrimer therapeutics for breast and gastric cancer | Protein Expression Facility | | 10.82292/sje9-sd81 | 2022-23 (Round 1) | Prof Brian Gabrielli | Mater Research Institute | Screen for compounds synthetically lethal with defective RB and p53 | Discovery Biology Griffith | | 10.82292/22fq-g666 | 2022-23 (Round 1) | Prof James St John | Griffith University | Spinal Injury Project: pilot-scale GMP production and validation of clinically compliant nerve bridges | Q-Gen Cell Therapeutics | | 10.82292/aewt-4120 | 2022-23 (Round 1) | Mr Robert Batchelor | Nutromics Pty Ltd | Surface plasmon resonance-based screening of DNA aptamers targeted to small molecule drugs | Monash Fragment Platform | | 10.82292/zgtp-y291 | 2022-23 (Round 1) Technical Feasibility Assessment | Dr Rhonda Taylor | The University of Western Australia (UWA) | Allele-selective CRISPR deletion as a therapy for ACTA1 congenital myopathy | Cell & Tissue Therapies WA | | 10.82292/yh3s-9n07 | 2022-23 (Round 1) Technical Feasibility Assessment | Prof Enzo Porrello | Murdoch Childrens Research Institute | Evaluating technical feasibility of cGMP production of bioengineered heart tissue to treat heart failure in congenital heart disease | Centre of Excellence in Cellular Immunotherapy | | 10.82292/3se1-yn33 | 2022-23 (Round 1) Technical Feasibility Assessment | A/Prof Anthony Kicic | Telethon Kids Institute | Making bacteriophage therapy a reality: Implementation of a novel treatment pipeline to treat antimicrobial-resistant infections. | Cell & Tissue Therapies WA | | 10.82292/w05g-f869 | 2022-23 (Round 1) Technical Feasibility Assessment | A/Prof Joshua Ooi | Monash University | Manufacture of autologous T regulatory cells modified ex vivo to express T cell receptors for autoimmune disease | Centre of Excellence in Cellular Immunotherapy | | 10.82292/s5rb-rc48 | 2022-23 (Round 1) Technical Feasibility Assessment | Dr Evan Wong | Royal Perth Hospital | Validation of GMP-compliant manufacture of corneal endothelial cells for injection | Cell & Tissue Therapies WA | | 10.82292/gcaa-bf28 | 2022-23 (Round 2) | Gregory Santamaria | Cyclotek (Aust) Pty Ltd | Development of novel fluorinated ligands of fibroblast activation protein, FAP, as diagnostic radiotracers of oncological disorders | Australian Translational Medicinal Chemistry Facility | | 10.82292/7t77-8r16 | 2022-23 (Round 2) | Dr Steven Suchting | Emenda Therapeutics Australia Pty Ltd | Development of SRPK1 kinase inhibitors for osteoarthritis pain | Centre for Drug Candidate Optimisation | | 10.82292/7esc-3t92 | 2022-23 (Round 2) | A/Prof David Ian Roper FRSC | University of Warwick,UK | Drug discovery for bacterial glycosyltransferases to combat AMR using the Monash Fragment Platform (MFP) screening facility | Monash Fragment Platform | | 10.82292/tde2-xa63 | 2022-23 (Round 2) | Dr Balaji Somasundaram | Denteric Pty Ltd | Enabling translation of a therapeutic vaccine candidate against Porphyromonas gingivalis | National Biologics Facility Queensland Node | | 10.82292/k6ra-dm24 | 2022-23 (Round 2) | Ms Reema Bajaj | Burnet Institute | Engineering IgG-like ACE2 antivirals against future pathogenic coronavirus events | National Biologics Facility Queensland Node | | 10.82292/65qn-ay35 | 2022-23 (Round 2) | Prof Fabienne Mackay | QIMR Berghofer Medical Research Institute | Large-scale production of a TACI-targeting antibody to test its therapeutic efficacy in a preclinical model of chronic lymphocytic leukaemia. | Protein Expression Facility | | 10.82292/vxq8-dk28 | 2022-23 (Round 2) | A/Prof Joshua Ooi | Monash University | Manufacture of autologous T regulatory cells modified ex vivo to express T cell receptors for autoimmune disease | Centre of Excellence in Cellular Immunotherapy | | 10.82292/h09v-qt40 | 2022-23 (Round 2) | Dr Chengxue Helena Qin | Monash University | Novel disease-modifying approach to treat pulmonary hypertension | Australian Translational Medicinal Chemistry Facility | | 10.82292/ejrx-cv73 | 2022-23 (Round 2) | A/Prof Ann Kwan | University of Sydney | Targeting FtsY for a new class of antibiotics | Monash Fragment Platform | | 10.82292/c2nc-hs42 | 2022-23 (Round 2) | Dr Evan Wong | Lions Eye Institute, Sir Charles Gairdner Hospital and Royal Perth Hospital | Validation of GMP-compliant manufacture of corneal endothelial cells for intraocular injection as an alternative to corneal transplantation | Cell & Tissue Therapies WA | | 10.82292/y7g4-xt28 | 2023-24 (Round 1) | Dr Sohinee Sarkar | Murdoch Children’s Research Institute | A stem cell powered drug discovery pipeline for non-tuberculous mycobacteria | Stem Cell Disease Modelling & Drug Screening Facility (MCRI) | | 10.82292/7tpw-d508 | 2023-24 (Round 1) | Dr Serena Duchi | University of Melbourne | Developing a GMP Compliant Adipose Derived Stem Cell Manufacturing Process for Cartilage Based Stem Cell Therapies | Cell & Molecular Therapies | | 10.82292/h0pk-x570 | 2023-24 (Round 1) | Dr David Jacques | University of New South Wales | Developing anti-capsid therapeutics for HTLV-1 | Monash Fragment Platform | | 10.82292/781r-w361 | 2023-24 (Round 1) | A/Prof Ian Street | Children's Cancer Institute | Developing METTL5 Inhibitors for the treatment of paediatric neuroblastoma and adult solid tumours | Australian Translational Medicinal Chemistry Facility and Centre for Drug Candidate Optimisation | | 10.82292/fscs-st66 | 2023-24 (Round 1) | Dr Aggie Susanti Lawer | University of Sydney | Developing Precision Covalent Therapeutics to Target Protein Disulfide Isomerase A6: A Novel and Safer Strategy Against Acute Ischaemic Stroke | GRIDD Mass Spectrometry Screening and Compounds Australia | | 10.82292/tp2b-8s57 | 2023-24 (Round 1) | Dr Rosalind Wilson | Carpe Vitae Pharmaceuticals | Development of a novel drug targeting age-related diseases | Centre for Drug Candidate Optimisation | | 10.82292/bbvh-xb24 | 2023-24 (Round 1) | Mr Miguel Aguirre | University of Queensland | Development of a vaccine to prevent Group A Streptococcus pharyngeal infection | Protein Expression Facility | | 10.82292/2f7w-jp96 | 2023-24 (Round 1) | Dr Steven Petratos | Monash University | Development of Integrin αVβ3 Agonists to Promote Remyelination in Multiple Sclerosis | Australian Translational Medicinal Chemistry Facility | | 10.82292/ften-d773 | 2023-24 (Round 1) | Dr Pegah Varamini | University of Sydney | Development of new nano-platforms for the treatment of triple negative breast cancer (TNBC). | Centre for Integrated Preclinical Drug Development | | 10.82292/3yqb-1104 | 2023-24 (Round 1) | Dr Natalie Borg | RMIT University | Development of novel agents targeting severe viral infections | CSIRO Biomedical Manufacturing | | 10.82292/tzwg-5b43 | 2023-24 (Round 1) | Prof Rachel Codd | The University of Sydney | Efficacy and toxicity measures of a new class of iron chelator | Centre for Drug Candidate Optimisation | | 10.82292/2mjv-sm96 | 2023-24 (Round 1) | Dr Sarah Jones | Monash University | Fragment screen for E3 ligase inhibitors | Monash Fragment Platform | | 10.82292/vd5s-yt78 | 2023-24 (Round 1) | A/Prof Matthew Piggott | University of Western Australia and Emyria Ltd | Hit to lead optimisation of novel drug candidates targeting mental health and neurodegenerative diseases. | Centre for Drug Candidate Optimisation | | 10.82292/x678-yt71 | 2023-24 (Round 1) | A/Prof Garron Dodd | The University of Melbourne | Identifying New Targets to Treat Metabolic Disease | Victorian Centre for Functional Genomics | | 10.82292/j8qe-yt55 | 2023-24 (Round 1) | Dr Jonathan Danon | The University of Sydney | Innovative Molecules for Imaging Neuroinflammation | Centre for Drug Candidate Optimisation | | 10.82292/a26z-mj46 | 2023-24 (Round 1) | A/Prof Andrew Wise | Bionics Institute | Optimisation of a therapeutic neurotrophin molecule to enable evaluation in a first in human clinical trial | CSIRO Biomedical Manufacturing | | 10.82292/9vpx-jc18 | 2023-24 (Round 1) | Dr Thomas Tapmeier | Monash University | Peripherally Restricted NPSR1 Antagonist in Endometriosis | Australian Translational Medicinal Chemistry Facility and Centre for Drug Candidate Optimisation | | 10.82292/34pm-ze18 | 2023-24 (Round 1) | Dr Willem Joost Lesterhuis | Telethon Kids Institute | Small molecule drugs in immuno-oncology | Centre for Drug Candidate Optimisation | | 10.82292/41v0-w038 | 2023-24 (Round 1) | Prof Tom Gonda | University of South Australia | Structure-Activity Analysis and Optimisation of Potential MYB-p300 Inhibitors | Australian Translational Medicinal Chemistry Facility | | 10.82292/z0jm-9r87 | 2023-24 (Round 1) | Dr Nicole Van Burgen | Murdoch Children’s Research Institute | Therapeutics for NAXD disorder – a newly described fatal encephalopathy triggered by fever | Stafford Fox Disease Modelling Facility | | 10.82292/0dz9-w981 | 2023-24 (Round 1) Technical Feasibility Assessment | Mr David Thomas Kneen | Celleo Biotech Pty Ltd | Automated aseptic manufacture of serum eye drops for patients suffering dry eye conditions | Cell & Tissue Therapies WA (Royal Perth Hospital) | | 10.82292/371z-db46 | 2023-24 (Round 1) Technical Feasibility Assessment | Prof Majid Ebrahimi Warkiani | SMART MCs Pty Ltd | Biodegradable Microcarriers for Therapeutic Stem Cells: A Feasibility Analysis for Large-Scale Production | Cell & Tissue Therapies WA (Royal Perth Hospital) | | 10.82292/2adk-w783 | 2023-24 (Round 1) Technical Feasibility Assessment | Prof David Gottlieb | Western Sydney Local Health District | Commercial scale up of CMV and EBV specific T-cell manufacturing | Centre of Excellence in Cellular Immunotherapy (Peter MacCallum Cancer Centre) | | 10.82292/p3j5-5925 | 2023-24 (Round 1) Technical Feasibility Assessment | Dr Anai Gonzalez Cordero | Children’s Medical Research Institute | Developing an ‘allogeneic stem cell-derived photoreceptor cell product’ compatible with good manufacturing practice (GMP) conditions. | Sydney Cell and Gene Therapy (Westmead Precinct) | | 10.82292/x1pq-hs83 | 2023-24 (Round 1) Technical Feasibility Assessment | A/Prof Jason Waithman | University of Western Australia | Improving adoptive cell therapy protocols through transcriptional rewiring of T cells | Cell & Tissue Therapies WA (Royal Perth Hospital) | | 10.82292/9s20-b112 | 2023-24 (Round 1) Technical Feasibility Assessment | Dr Saparna Pai | James Cook University | Retrieving short-term memories for tuberculosis treatment | Q-Gen Cell Therapeutics (QIMR Berghofer) | | 10.82292/gdqh-tz30 | 2023-24 (Round 2) | Dr Dhuong Nhu | University of Melbourne | Bioconjugation and characterisation of novel Antibody-Drug Conjugates for in vivo (mouse) studies targeting breast cancer | CSIRO Biomedical Manufacturing | | 10.82292/mbxj-ct59 | 2023-24 (Round 2) | Dr Ruth Thornton | Telethon Kids Institute | Blitz-OM- development of a slow-release anti-biofilm treatment to prevent the need for recurrent grommet surgery | CSIRO Biomedical Manufacturing | | 10.82292/scb6-0t61 | 2023-24 (Round 2) | A/Prof Charlene Kahler | University of Western Australia | Breaking ceftriaxone resistance in Neisseria gonorrhoeae using an inhibitor of lipid A phosphethanolamine transferase (EptA) | Monash Fragment Platform | | 10.82292/2172-vv92 | 2023-24 (Round 2) | Dr Sofia Burgener | University of Queensland | Caspase-1 inhibitors for the treatment of inflammatory disease | Compounds Australia, Queensland Emory Drug Discovery Initiative and Mass Spectrometry Screening Platform | | 10.82292/03zp-yt46 | 2023-24 (Round 2) | A/Prof Kathryn Fay Tonissen | Griffith University | Characterisation of covalent binders for a potential new drug target in oncology, Carbonic Anhydrase 3 | Compounds Australia and Mass Spectrometry Screening Platform | | 10.82292/mfv6-5051 | 2023-24 (Round 2) | Dr Lucia Florencia Zacchi | University of Queensland | Characterisation of novel antibodies for the treatment of neuropathic pain | National Biologics Facility | | 10.82292/2smv-hr94 | 2023-24 (Round 2) | Dr Adam Johnson | Skin2Neuron | Development of automated manufacture of hair follicle-derived neuroprecursors for GLP-Tox IND-enabling studies | Biologics Innovation Facility | | 10.82292/bcc9-1p43 | 2023-24 (Round 2) | Scientia A/Prof Nadeem Kaakoush | University of New South Wales | Discovery of novel therapeutic compounds targeting the microbiome-immune axis in ulcerative colitis | ANU Centre for Therapeutic Discovery | | 10.82292/6swt-n012 | 2023-24 (Round 2) | Dr Michael Nafisinia | Westmead institute for Medical Research | Enhancing Therapeutic Efficacy: Pioneering Large-Scale Drug Pipeline Development and Testing on PKU Patients' iPSC-Derived Hepatocytes | ACRF Drug Discovery Centre for Childhood Cancer | | 10.82292/8nmp-zn65 | 2023-24 (Round 2) | A/Prof Greg Arndt | Children's Cancer Institute | Hit identification using DEL for the development of small molecule targeted treatment of osteosarcomas | Monash Fragment Platform | | 10.82292/c6fn-4v12 | 2023-24 (Round 2) | Dr Hannah Kelly | Australian National University | Improving mRNA vaccines with precision vaccinology | UNSW RNA Institute | | 10.82292/eazt-fz05 | 2023-24 (Round 2) | Dr Natalie Diepenhorst | Monash University | Lead discovery for the orphan GPCR, GPR88 | Monash Fragment Platform | | 10.82292/9pnp-mc26 | 2023-24 (Round 2) | A/Prof Danielle Stanisic | Griffith University | Manufacturability assessment of a whole parasite malaria vaccine | CSIRO Biomedical Manufacturing | | 10.82292/ax43-0433 | 2023-24 (Round 2) | Dr Rabina Giri | Mater Research Institute | Microbiome derived IBD small molecule | Queensland Emory Drug Discovery Initiative | | 10.82292/cyj5-hc64 | 2023-24 (Round 2) | Dr Makutiro Masavuli | Basil Hetzel Institute (BHI) for Translational Health Research | mRNA vaccine for HCV | BASE Facility | | 10.82292/y6tz-4436 | 2023-24 (Round 2) | Dr Louise Robertson | University of Adelaide | Next-generation CRISPR therapeutics for autosomal dominant retinitis pigmentosa | Vector and Genome Engineering Facility and South Australia Genome Editing Facility | | 10.82292/ftvt-cz86 | 2023-24 (Round 2) | Prof Mohammed Akhter Hossain | Florey Institute of Neuroscience and Mental Health | Novel brain peptide receptor analgesics: Accelerated target validation and pre-clinical testing of RXFP3 activators | Centre for Integrated Preclinical Drug Development | | 10.82292/k8zs-8q56 | 2023-24 (Round 2) | Dr Rohan Volpe | Walter and Eliza Hall Institute of Medical Research | Pharmacokinetic profiling of two novel antiviral coronavirus protease inhibitors towards clinical application for COVID-19 and beyond. | Centre for Drug Candidate Optimisation | | 10.82292/6w34-4797 | 2023-24 (Round 2) | Prof Chris Langmead | Phrenix Therapeutics Pty Ltd | Pre-candidate selection for novel schizophrenia therapeutics | Centre for Drug Candidate Optimisation | | 10.82292/4gdy-fd17 | 2023-24 (Round 2) | Michael Grant | Q-Sera Pty Ltd | RAPClot bioassay validation and optimisation | CSIRO Biomedical Manufacturing | | 10.82292/zpce-nm72 | 2023-24 (Round 2) | Dr Rhys Parry | University of Queensland | Self-amplifying RNAs with modified NTPs: a next-generation vaccine and therapeutic platform. | BASE Facility | | 10.82292/wmpm-vj58 | 2023-24 (Round 2) | A/Prof Antoine de Weck | Children's Cancer Institute | The druggable transcriptome: Small Molecules inducing Reading Frame Stops (SMIRFS) | ACRF Drug Discovery Centre for Childhood Cancer | | 10.82292/mdm8-ag21 | 2023-24 (Round 2) | Prof Stephanie Watson | University of Sydney | Transforming corneal stem cell-based therapies with innovative bioengineered technologies | CSIRO Biomedical Manufacturing | | 10.82292/5m3a-9g17 | 2023-24 (Round 2) Technical Feasibility Assessment | Dr Sarah Sutherland | Chris O’Brien Lifehouse | Exploring the Feasibility of Tumour Infiltrating Lymphocyte (TIL) Therapy in Appendiceal Cancer | Cell & Molecular Therapies | | 10.82292/h1ep-zz28 | 2023-24 (Round 2) Technical Feasibility Assessment | Dr Yvette Wooff | Australian National University | Red blood cell-extracellular vesicles to treat retinal degenerative diseases. | Centre of Excellence in Cellular Immunotherapy | | 10.82292/9n3a-ma52 | 2024-25 (Round 1) | A/ Prof Nicholas Veldhuis | Monash Institute of Pharmaceutical Sciences | Assessing efficacy of new generation analgesic nanoparticles for osteoarthritic pain | Centre for Integrated Preclinical Drug Development | | 10.82292/xebv-6805 | 2024-25 (Round 1) | Prof Carl Walkley | Hudson Institute of Medical Research and Monash University | Developing new therapies to treat ADAR1 mutant disease. | ANU Centre for Therapeutic Discovery | | 10.82292/4eb3-8w96 | 2024-25 (Round 1) | A/ Prof Zi (Sophia) Gu | University of New South Wales | Development of a mRNA nanoparticle formulation for low back pain treatment | RNA Institute | | 10.82292/kyaa-m164 | 2024-25 (Round 1) | Dr Rebecca Nisbet | Florey Institute of Neuroscience and Mental Health | Development of an active immunotherapy for Alzheimer's disease | mRNA CORE | | 10.82292/jwz9-cx37 | 2024-25 (Round 1) | Dr Stephan Brouwer | Institute for Molecular Bioscience (UQ) | Development of an optimised vaccine formulation to prevent Group A Streptococcus infection | Protein Expression Facility | | 10.82292/kymr-0n02 | 2024-25 (Round 1) | Mrs Harsha Gupta | Cynata Therapeutics Limited | Development of cryopreserved wound patches with stem cells ready for thawing at point of care | Cell & Tissue Therapies WA (Royal Perth Hospital) | | 10.82292/bdjv-af82 | 2024-25 (Round 1) | Dr Ioanna Savvidou | Monash university | Development of endothelial targeted-CD39 as a novel treatment for micro circulatory thrombosis in stroke and global brain ischaemia. | Biologics Innovation Facility | | 10.82292/memn-sy04 | 2024-25 (Round 1) | Prof Peter Currie | Australian Regenerative Medicine Institute | Development of NAMPT-cif Fc fusion for treatment of muscle disease | CSIRO Biomedical Manufacturing | | 10.82292/1298-mm91 | 2024-25 (Round 1) | Dr Kavitha Gowrishankar | Kids Research Institute, Children’s Hospital Westmead | EphA2 Chimeric Antigen Receptor (CAR) T cell Therapy for Children with Bone Tumours: A Phase I Clinical Trial | Sydney Cell and Gene Therapy (Westmead Precinct) | | 10.82292/1ekw-8q64 | 2024-25 (Round 1) | Dr Rosemary Cater | Institute for Molecular Bioscience (UQ) | FLVCR2 inhibition for the treatment of glioblastoma | Compounds Australia, Qld Emory Drug Discovery Initiative and IBG-Nathan Mass Spec Facility | | 10.82292/w083-zr74 | 2024-25 (Round 1) | Dr Mai Ngoc Vu | University of Melbourne | Harnessing mRNA Lipid Nanoparticles For Efficient Delivery Of Influenza Monoclonal Antibody Therapeutics | BASE Facility | | 10.82292/4wg2-2a33 | 2024-25 (Round 1) | Dr Nicole van Bergen | Murdoch Children’s Research Institute | High-throughput drug screening for paediatric epilepsy due to pathogenic variants in CDKL5 | Compounds Australia and Stem Cell Disease Modelling & Drug Screening Facility | | 10.82292/hszt-te09 | 2024-25 (Round 1) | A/ Prof Willem Joost Lesterhuis | Kids Research Institute Australia | Lead-to-candidate optimisation of a small molecule oncology drug | Centre for Drug Candidate Optimisation | | 10.82292/ghqt-pw57 | 2024-25 (Round 1) | Dr Bijay Dhungel | Centenary Institute | Muscle-targeted adeno-associated viruses for safer gene therapy | Vector and Genome Engineering Facility (CMRI) | | 10.82292/b9s5-7m04 | 2024-25 (Round 1) | Dr Chengxue Helena Qin | Monash University | Novel disease-modifying approach to treat pulmonary hypertension | Australian Translational Medicinal Chemistry Facility | | 10.82292/dyqt-9y77 | 2024-25 (Round 1) | Prof Bryan Day | QIMR Berghofer Medical Research Institute | Novel Eph Receptor Antibody Drug Conjugate Therapy Development for the Treatment of Paediatric Brain Cancer | National Biologics Facility | | 10.82292/2paq-nn75 | 2024-25 (Round 1) | A/ Prof Michelle Wykes | QIMR Berghofer/ Fovero Therapeutics | Novel therapy for cancer | CSIRO Biomedical Manufacturing | | 10.82292/4wff-yt84 | 2024-25 (Round 1) | Dr Sheng Yu Ang | Neuromedicines Discovery Centre (NDC) | Potent and selective non-hallucinogenic serotonin 2A receptor agonists for the treatment of severe mental health disorders | Australian Translational Medicinal Chemistry Facility | | 10.82292/wzy9-rj34 | 2024-25 (Round 1) | A/ Prof Richard Gordon | Queensland University of Technology | Screening and validation of novel therapeutic agents for inflammation resolution and neuroprotection in Parkinson's disease | Compounds Australia | | 10.82292/1pya-8686 | 2024-25 (Round 1) | Prof Katherine Andrews | Griffith University | Screening chemically diverse compounds that represent untested chemical space for activity against Plasmodium malaria parasites | National Drug Discovery Centre | | 10.82292/z7mj-0359 | 2024-25 (Round 1) | Dr Aude Dorison | Murdoch Children’s Research Institute | Screening for new treatments for glomerular disease with a new stem cell reporter line | "Stem Cell Disease Modelling & Drug Screening Facility Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility (MCRI)" | | 10.82292/2y4k-jn58 | 2024-25 (Round 1) | Dr Ralph Patrick | Institute for Molecular Bioscience, The University of Queensland | Synthesis and Characterization of Transcription Factor Inhibitors for Therapeutic Interventions in Age-Related Conditions | Centre for Drug Candidate Optimisation and Qld Emory Drug Discovery Initiative | | 10.82292/4zhk-sn82 | 2024-25 (Round 1) | Dr Brian Liddicoat | exteRNA | Targeting novel RNA biology in cancer | Monash Fragment Platform | | 10.82292/9mfa-s753 | 2024-25 (Round 1) | Dr Frances Evesson | Children’s Medical Research Institute and Sydney Children’s Hospitals Network | Therapeutic possibilities for PYROXD1 myopathy | mRNA CORE | | 10.82292/dq67-xw61 | 2024-25 (Round 1) | Dr Dannel Yeo | Centenary Institute | Tumour infiltrating lymphocyte therapy for appendiceal cancer | Cell & Molecular Therapies (Royal Prince Alfred Hospital) | | 10.82292/9tyt-vv45 | 2024-25 (Round 1) Technical Feasibility Assessment | A/ Prof Elizabeth Ng | Murdoch Children’s Research Institute | Autologous haematopoietic stem cells, moving transplantation into the 21st century | Cell Therapies | | 10.82292/3a7b-dy07 | 2024-25 (Round 2) | Dr Nicholas Hunt | Endo Axiom | A GLP repeat dose oral toxicity study of Endo Axiom’s inverse vaccine for prevention of type 1 diabetes | Agilex Biolabs | | 10.82292/bj7v-1986 | 2024-25 (Round 2) | Professor Claudine Bonder | University of South Australia | Advancing a ‘first-in-class’ monoclonal antibody to combat cancer. | CSIRO Biomedical Manufacturing | | 10.82292/pbek-9241 | 2024-25 (Round 2) | Dr Behnaz Heydarchi | Walter and Eliza Hall Instittite | Advancing a novel therapy for the prevention of haemolytic disease of the foetus and newborn | National Biologics Facility | | 10.82292/fbwx-c890 | 2024-25 (Round 2) | Dr Frankie Butera | Murdoch Children’s Research Institute | Assessing the pharmacokinetic profile of small molecules to promote cardiomyocyte specific proliferation | Centre for Drug Candidate Optimisation | | 10.82292/9jdh-ny35 | 2024-25 (Round 2) | Dr Steve Dingwall | University of Queensland | Bi-specific proteins for the enhancement of pluripotent stem cell derived heart muscle grafts | Protein Expression Facility | | 10.82292/jfp4-6773 | 2024-25 (Round 2) | Dr Rudrarup Bhattacharjee | University of Adelaide | Deciphering the mechanism of Rubinstein-Taybi Neurodevelopmental Syndrome and screening new therapeutic options | Functional Genomics South Australia | | 10.82292/9cy6-tf80 | 2024-25 (Round 2) | Dr Joanne Casey | Immuron Limited | Design, Scale-up and Manufacturability of a Safe and Effective TcdB Immunogen to Support the Development of an Oral Therapy for the Treatment of Clostridioides difficile infections. | CSIRO Biomedical Manufacturing | | 10.82292/g7eh-0107 | 2024-25 (Round 2) | Dr Maria Garone | Murdoch Children's Research Institute | Development of a high-throughput drug screening platform for paediatric brain tumours using advanced cancer-brain organoid models | Drug Discovery Facility | | 10.82292/d61r-9h72 | 2024-25 (Round 2) | Dr Keith Sia | Children’s Cancer Institute | Development of a novel METTL1-specific PROTAC protein degrader | Recombinant Protein Facility, ACRF Drug Discovery Centre for Childhood Cancer | | 10.82292/mbr4-xx28 | 2024-25 (Round 2) | Professor Gregory Cook | Queensland University of Technology | Development of anti-virulence strategies to combat MDR gram-negative pathogens | IBG-Nathan Mass Spec Facility | | 10.82292/tsjr-g881 | 2024-25 (Round 2) | Dr Diyana Hassanel | Garvan Institute of Medical Research | Development of targeted mRNA vaccines for liver cancer | mRNA CORE | | 10.82292/d5hz-vz87 | 2024-25 (Round 2) | Dr Gilbert Song | University of Queensland | Discovery of MyD88 inhibitors for novel anti-inflammatory and anti-cancer therapy | Monash Fragment Platform | | 10.82292/7k4v-gk61 | 2024-25 (Round 2) | Prof Joseph Trapani | University of Melbourne | Drugs that block lymphocyte perforin - focused immunosuppressive agents for auto-immune and post-infectious pathologies | Medicines Manufacturing Innovation Centre | | 10.82292/vdtg-x225 | 2024-25 (Round 2) | Dr Mehdi Tabar | Centenary Institute | Epigenetic-directed drug development for type I interferonopathies | National Drug Discovery Centre | | 10.82292/exbs-dd58 | 2024-25 (Round 2) | Dr Zhi Ying Kho | Monash University | High-Throughput Phenotypic and Target-Based Profiling of Novel Antimicrobials Using Imaging and Proteomics | National Drug Discovery Centre | | 10.82292/f721-2980 | 2024-25 (Round 2) | Dr Charles Bailey | Centenary Institute | Improving the accessibility of adeno-associated virus (AAV) gene therapy | RNA Institute | | 10.82292/x821-fs14 | 2024-25 (Round 2) | Dr Stephen Huang | Mater Research Institute | In vivo macrophage modulation | Centre for Integrated Preclinical Drug Development , National Biologics Facility | | 10.82292/hb1z-ar16 | 2024-25 (Round 2) | Dr Yi David Ju | La Trobe University | In Vivo mRNA CAR T Cell Engineering via Targeted Lipid Nanoparticles | BASE Facility | | 10.82292/5jb0-f025 | 2024-25 (Round 2) | A/Prof Michelle Wykes | QIMR Berghofer/ Fovero Therapeutics | Novel therapy for cancer | Agilex Biolabs | | 10.82292/4zed-e944 | 2024-25 (Round 2) | Prof Rebecca Ritchie | Monash University | Optimisation of a new class of inflammation-resolving GPCR agonists for the treatment of Heart Failure with preserved Ejection Fraction (HFpEF) | National Drug Discovery Centre | | 10.82292/9p16-cd72 | 2024-25 (Round 2) | Prof Colin Pouton | Monash University | Optimisation of AAK1 gene knockdown for treatment of chronic pain | RNA Institute | | 10.82292/a82n-7s47 | 2024-25 (Round 2) | Dr Lipin Loo | University of Sydney | Optimising Scale-Up Manufacturing for Cutting-Edge mRNA Pain Relief | RNA Institute | | 10.82292/b8dx-kd78 | 2024-25 (Round 2) | Dr Clare Slaney | Peter MacCallum Cancer Centre | Overcoming the heterogeneity of cancer antigen expression with an mRNA vaccine and precision LNP delivery. | mRNA CORE | | 10.82292/tcsk-8z68 | 2024-25 (Round 2) | Dr Thomas Tapmeier | Monash University | Peripherally Restricted NPSR1 Antagonist in Endometriosis | Australian Translational Medicinal Chemistry Facility | | 10.82292/j5ja-e549 | 2024-25 (Round 2) | Dr Julie Monk | Resseptor Therapeutics | Preparation of ADC and Radiotheranositics from our Nvel Covalently Binding T Cell Receptor Against Tumour-Associated Peptide–MHC Complex | Protein Expression Facility | | 10.82292/mc5c-z687 | 2024-25 (Round 2) | Prof Christopher Sweeney | University of Adelaide | SAi001 Pharmacokinetic Bridging Study | Agilex Biolabs | | 10.82292/qa2k-0190 | 2024-25 (Round 2) | Dr Zohaib Rana | Fold AI (RNAFold.AI Pty Ltd) | Targeting Pathogenic Genes in Spinocerebellar Ataxia Using Novel Antisense Oligonucleotides | RNA Institute | | 10.82292/vb12-8g43 | 2024-25 (Round 2) | Dr David Leaver | Charles Sturt University | Targeting sterol metabolism as a way to kill parasitic worms | Compounds Australia, ANU Centre for Therapeutic Discovery | | 10.82292/jc4g-4q71 | 2024-25 (Round 2) | Dr Melanie Robitaille | University of Queensland | TRPC3 inhibitors for the treatment of cardiac disease | Compounds Australia, QEDDI, IBG-Nathan Mass Spec Facility | | 10.82292/59hx-0x76 | 2024-25 (Round 2) Technical Feasibility Assessment | Dr Saparna Pai | TAARA Therapeutics Pty Ltd | Retrieving short-term memories for treatment of post-TB lung disease | Q-Gen Cell Therapeutics | | 10.82292/ze94-z580 | 2025-26 (Round 1) | Dr Rodrigo Maron Carlessi | Curtin Medical Research Institute | A Programmable RNA Therapy Platform to Treat Liver Cancer | RNA Innovation Foundry | | 10.82292/cx49-d747 | 2025-26 (Round 1) | Dr Mitali Sarkar-Tyson | University of Western Australia | Advanced Optimisation of Antivirulence Compounds Against Bacterial Pathogens | Centre for Drug Candidate Optimisation | | 10.82292/n7te-z623 | 2025-26 (Round 1) | Dr Adam Johnson | Skin2Neuron | Aseptic process simulation runs enabling clinical manufacture of Primaverah for Phase 1/2A clinical use | Q-Gen Cell Therapeutics | | 10.82292/2qy1-s306 | 2025-26 (Round 1) | A/Prof Colm Keane | University of Queensland | BrainCAR19 Study - Treatment of relapsed Primary Brain Lymphoma with CD19 directed CAR-T cells | Sydney Cell and Gene Therapy | | 10.82292/t8w6-7q06 | 2025-26 (Round 1) | Professor Arnold Lining Ju | University of Sydney | Comparative Investigation of Adenovirus and Adeno-Associated Virus Protein Interfaces in the Context of Thrombosis | Vector and Genome Engineering Facility, Recombinant Products Facility | | 10.82292/9pqz-k845 | 2025-26 (Round 1) | Dr Ben Wylie | UWA Centre for Child Health Research | Developing a biomaterial for intra-operative delivery of mRNA therapeutics targeting the tumour microenvironment | CSIRO Biomedical Manufacturing | | 10.82292/frhp-5219 | 2025-26 (Round 1) | Dr Gabriel Duette | Westmead Institute for Medical Research | Developing immunotherapies to enhance CD8 T-cell-mediated clearance of HIV-1-infected cells | mRNA CORE | | 10.82292/a6d5-nf15 | 2025-26 (Round 1) | Dr Stefka Tasheva | University of Adelaide | Developing Precision Medicine Therapies for PCDH19-Clustering Epilepsy | Functional Genomics SA | | 10.82292/1gb6-8028 | 2025-26 (Round 1) | Dr Adam Thomas | Burnet Institute | Developing the first multi-species malaria vaccine to provide worldwide protection | mRNA CORE | | 10.82292/367r-3672 | 2025-26 (Round 1) | Dr Kevin Sek | Peter MacCallum Cancer Centre | Developing the next generation of cancer mRNA therapeutics | BASE Facility | | 10.82292/pcp8-zf86 | 2025-26 (Round 1) | Mrs Aneta Nash | ThyX Pty Ltd | Development and Assessment of Levothyroxine Implant | Medicines Manufacturing Innovation Centre | | 10.82292/ved0-ge05 | 2025-26 (Round 1) | Dr Siyang Ding | La Trobe University | Development of a high-throughput phenotypic screen for lysosomal storage disorders | Compounds Australia, National Drug Discovery Centre | | 10.82292/djzx-gw58 | 2025-26 (Round 1) | Professor Nicodemus Tedla | University of New South Wales | Development of a novel treatment option for post-sepsis acute lung injury (ALI) | CSIRO Biomedical Manufacturing | | 10.82292/gw81-9r91 | 2025-26 (Round 1) | Dr Shadabul Haque | Medicines Manufacturing Innovation Centre | Development of an Inhaled siRNA Therapeutic Targeting TNF-α for Pulmonary Inflammation | RNA Institute | | 10.82292/a6kd-2y46 | 2025-26 (Round 1) | Professor Greg Monteith | University of Queensland | Development of an Oral Solid Dosage Formulation of Novel Prostate Cancer TRPV6 Inhibitor QED-203 | Medicines Manufacturing Innovation Centre | | 10.82292/9nvw-ps38 | 2025-26 (Round 1) | Dr Grace Mennen | Monash Institute of Pharmaceutical Science | Development of Novel Small Molecules for Therapeutic Intervention in Pulmonary Arterial Hypertension (PAH) | National Drug Discovery Centre | | 10.82292/dcge-4y22 | 2025-26 (Round 1) | Dr Jordan Wright | Murdoch Children's Research Institute | Discovery of new treatments for brain development disorders linked to epigenetic regulatory genes | Compounds Australia, Drug Discovery Facility, Victorian Centre for Functional Genomics | | 10.82292/zgqk-dk56 | 2025-26 (Round 1) | Dr Edmund Yin Man Chung | University of Sydney | In-vivo generation of chimeric antigen receptor (CAR) T-cells using lipid nanoparticles to treat autoimmune kidney disease | RNA Institute | | 10.82292/d6sy-qj19 | 2025-26 (Round 1) | Dr Richard Foitzik | Inosi Therapeutics | IRAP Inhibitor Manufacturing | Ab Initio Pharma, Australian Genome Research Facility | | 10.82292/83n3-wk32 | 2025-26 (Round 1) | Dr Travis Stiles | Novoroo Bioscience Pty Ltd | LRP1 Antagonist to Block Interneuronal Spread of Tau in Alzheimer's Disease | Monash Fragment Platform | | 10.82292/see7-kg74 | 2025-26 (Round 1) | Professor James Hudson | QIMR Berghofer | New Generation Specific Epigenetic Inhibitors for Heart Failure | National Drug Discovery Centre | | 10.82292/16ph-nh49 | 2025-26 (Round 1) | Dr Daryl Ariawan | Macquarie University | Next-Generation Small Molecules for Alzheimer’s Therapy | Centre for Drug Candidate Optimisation | | 10.82292/dteg-qw42 | 2025-26 (Round 1) | Ms Alison Roennfeldt | University of Adelaide | Novel Small Molecule FIH Inhibitors for Treatment of Metabolic Disease | Centre for Drug Candidate Optimisation, Queensland Emory Drug Discovery Initiative | | 10.82292/7rzm-yx25 | 2025-26 (Round 1) | Dr Shea Carter | QIMR Berghofer | Novel Small Molecule G9a Inhibitors for Treating Colon and Liver Cancers | Queensland Emory Drug Discovery Initiative, Protein Expression Facility | | 10.82292/8m4q-w475 | 2025-26 (Round 1) | Dr Amila Suraweera | Queensland University of Technology | Optimisation of a novel small molecule inhibitor for the treatment of lung cancer | Australian Translational Medicinal Chemistry Facility | | 10.82292/rs6v-tw49 | 2025-26 (Round 1) | Professor Rachel Codd | University of Sydney | Pharmacokinetics of Next-Generation Iron Chelators | Centre for Drug Candidate Optimisation, National Deuteration Facility | | 10.82292/tcmp-8860 | 2025-26 (Round 1) | A/ Prof Arnold Lining Ju | University of Sydney | Regulation of Adenovirus–Protein Interfaces as a Therapeutic Strategy in Thrombosis | Recombinant Products Facility | | 10.82292/v67t-zg84 | 2025-26 (Round 1) | A/Prof Iain Duggin | University of Technology Sydney | Scaling up the manufacture of an mRNA vaccine for the prevention of urinary tract infection | Biologics Innovation Facility, Recombinant Products Facility, RNA Institute | | 10.82292/wdbf-gm92 | 2025-26 (Round 1) | Dr Kiymet Bozaoglu | Murdoch Children’s Research Institute | Using patient-derived stem cell models to identify new therapies for NF1 Neurodevelopmental Disorders | Compounds Australia, Drug Discovery Facility | | 10.82292/hbrw-rw97 | 2025-26 (Round 1) Technical Feasibility Assessment | A/Prof Shireen Lamande | Murdoch Children's Research Institute (MCRI) | Products for Cartilage and Bone Repair using Human Induced Pluripotent Stem Cell-Derived Organoids and Decellularized Organoid Scaffolds | Cell Therapies Pty Ltd | | DOI |